HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has covered health care and the biopharma industry for over 12 years. He started out covering retail pharmacy for Drug Store News and shifted to writing for the pharma audience at BioPharm Insight, where highlights of his coverage included breaking stories about the early growing pains of CAR-T cell therapy development. Most recently he covered the biopharma beat at MedCity News. His professional interests include cell and gene therapies, hematology-oncology and the intersection of biopharma with artificial intelligence and machine learning. A native of Seattle, he holds a bachelor degree in journalism from Ball State University and also lived in China for three years. He is currently based in Brooklyn. Outside of work, Alaric’s interests include reading, coin collecting, travel and languages.

Latest From Alaric DeArment

Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?

Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.

Research & Development Clinical Trials

Sarepta Charges Ahead With DMD Gene Therapy Despite Setback

The company plans to start its Phase III trial of SRP-9001 in the middle of this year, with a potential readout by the end of 2022.

Research & Development Research and Development Strategies

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Commercial Approvals

GSK Antibody Appears Effective In Older COVID-19 Patients

With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.

Research & Development Research and Development Strategies

Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug

Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.

Research & Development Deals

Beam Looks Beyond Liver With Guide Therapeutics Acquisition

Research & Development BioPharmaceutical
See All
UsernamePublicRestriction

Register